Hologic (NASDAQ:HOLX) Rating Lowered to Hold at Argus

Argus cut shares of Hologic (NASDAQ:HOLX) from a buy rating to a hold rating in a report issued on Monday morning, MarketBeat Ratings reports.

Other equities analysts have also issued research reports about the company. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada lowered their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Morgan Stanley lowered their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $85.77.

Hologic Trading Down 0.2 %

HOLX opened at $63.27 on Monday. Hologic has a 52 week low of $62.69 and a 52 week high of $84.67. The business has a fifty day simple moving average of $68.98 and a 200-day simple moving average of $75.78. The firm has a market cap of $14.20 billion, a P/E ratio of 19.96, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Hologic in the 4th quarter valued at $28,269,000. Jefferies Financial Group Inc. grew its stake in shares of Hologic by 141.5% during the 4th quarter. Jefferies Financial Group Inc. now owns 96,849 shares of the medical equipment provider’s stock valued at $6,982,000 after buying an additional 56,742 shares during the period. Forum Financial Management LP purchased a new stake in shares of Hologic during the 4th quarter valued at $324,000. Toronto Dominion Bank grew its stake in shares of Hologic by 7.9% during the 4th quarter. Toronto Dominion Bank now owns 124,308 shares of the medical equipment provider’s stock valued at $8,961,000 after buying an additional 9,076 shares during the period. Finally, North Star Asset Management Inc. grew its stake in shares of Hologic by 0.3% during the 4th quarter. North Star Asset Management Inc. now owns 252,857 shares of the medical equipment provider’s stock valued at $18,228,000 after buying an additional 687 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.